Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03345342




Registration number
NCT03345342
Ethics application status
Date submitted
14/11/2017
Date registered
17/11/2017
Date last updated
15/09/2023

Titles & IDs
Public title
A Study of Paliperidone Palmitate 6-Month Formulation
Scientific title
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation
Secondary ID [1] 0 0
R092670PSY3015
Secondary ID [2] 0 0
CR108390
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Schizophrenia 0 0
Condition category
Condition code
Mental Health 0 0 0 0
Schizophrenia

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - PP6M
Treatment: Drugs - PP3M 350 mg eq.
Treatment: Drugs - PP3M 525 mg eq.
Treatment: Drugs - PP1M
Other interventions - Placebo

Experimental: PP1M: Transition Phase - Participants who previously have not achieved stability with moderate to higher doses of Paliperidone palmitate 1-month (PP1M) or Paliperidone palmitate 3-month (PP3M) will enter into a transition period of up to 4 months. During transition period participants will receive 1 to 5 injections of PP1M 50 to 100 milligrams equivalent (mg eq.). The participants who achieved stability (stability is defined as at least 3 months of injections with the last 2 doses being the same strength) with PP1M 100 mg eq. will precede from transition phase to maintenance phase.

Experimental: PP1M/PP3M: Maintenance Phase - All the participants will receive only 1 dose of PP1M 100 or 150 mg eq. or PP3M 350 or 525 mg eq. The participants will precede from maintenance phase to double-blind phase.

Experimental: PP6M or Placebo: Double-Blind Phase - Participants will receive intramuscular injection of PP6M in left gluteal muscle on Day 1 and right gluteal muscle on Day 183 with alternating placebo in right gluteal muscle on Day 92 and left gluteal muscle on Day 274.

Experimental: PP3M: Double-Blind Phase - Participants will receive intramuscular injections of PP3M at dose of 350 mg eq. or 525 mg eq. in left gluteal muscle on Day 1 and 274 and right gluteal muscle on Day 92 and 183.


Treatment: Drugs: PP6M
Participants will receive intramuscular injection of PP6M.

Treatment: Drugs: PP3M 350 mg eq.
Participants will receive intramuscular injection of PP3M 350 mg eq.

Treatment: Drugs: PP3M 525 mg eq.
Participants will receive intramuscular injection of PP3M 525 mg eq.

Treatment: Drugs: PP1M
Participants will receive intramuscular injection of PP1M 50 to 150 mg eq.

Other interventions: Placebo
Participants will receive matching placebo.
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to Relapse During the Double-Blind (DB) Phase
Timepoint [1] 0 0
Up to 12 months of DB Phase
Secondary outcome [1] 0 0
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score
Timepoint [1] 0 0
Baseline (DB) to 12 Months of DB Phase
Secondary outcome [2] 0 0
Change From Baseline in the Clinical Global Impression - Severity (CGI-S) Score
Timepoint [2] 0 0
Baseline (DB) to 12 Months of DB Phase
Secondary outcome [3] 0 0
Change From Baseline in the Personal and Social Performance (PSP) Scale Total Score
Timepoint [3] 0 0
Baseline (DB) to 12 Months of DB Phase
Secondary outcome [4] 0 0
Percentage of Participants With Symptomatic Remission Based on PANSS Score During DB Phase
Timepoint [4] 0 0
Up to 12 months of DB Phase
Secondary outcome [5] 0 0
Change From Baseline in the Satisfaction With Participants in Social Roles (SPSR) Score
Timepoint [5] 0 0
Baseline (DB) to 12 Months of DB Phase
Secondary outcome [6] 0 0
Change From Baseline in the Treatment Satisfaction Questionnaire for Medication (TSQM-9) Total Score
Timepoint [6] 0 0
Baseline (DB) to 12 Months of DB Phase
Secondary outcome [7] 0 0
Change From Baseline in the Simpson-Angus Rating Scale (SAS) Total Score
Timepoint [7] 0 0
Baseline (DB) to 12 Months of DB Phase
Secondary outcome [8] 0 0
Number of Participants With Symptoms of Akathisia Assessed Using Barnes Akathisia Rating Scale (BARS) Score
Timepoint [8] 0 0
Up to 12 Months of DB Phase
Secondary outcome [9] 0 0
Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) Total Score
Timepoint [9] 0 0
Baseline (DB) to 12 Months of DB Phase
Secondary outcome [10] 0 0
Number of Participants Based on Columbia Suicide Severity Rating Scale (C-SSRS) Total Score
Timepoint [10] 0 0
Baseline and endpoint (12 Months of DB Phase)
Secondary outcome [11] 0 0
Number of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Values During DB Phase
Timepoint [11] 0 0
Baseline (DB) to 12 Months of DB Phase
Secondary outcome [12] 0 0
Change From Baseline in the Body Mass Index (BMI) During DB Phase
Timepoint [12] 0 0
Baseline (DB) to 12 Months of DB Phase
Secondary outcome [13] 0 0
Change From Baseline in the Waist Circumference During DB Phase
Timepoint [13] 0 0
Baseline (DB) to 12 Months of DB Phase
Secondary outcome [14] 0 0
Change From Baseline in the Body Weight During DB Phase
Timepoint [14] 0 0
Baseline (DB) to 12 Months of DB Phase
Secondary outcome [15] 0 0
Change From Baseline in the Vital Signs (Pulse Rate) During DB Phase
Timepoint [15] 0 0
Baseline (DB) to 12 Months of DB Phase
Secondary outcome [16] 0 0
Change From Baseline in the Vital Signs (Systolic Blood Pressure [SBP] and Diastolic Blood Pressure [DBP]) During DB Phase
Timepoint [16] 0 0
Baseline (DB) to 12 Months of DB Phase
Secondary outcome [17] 0 0
Change From Baseline in Positive and Syndrome Scale (PANSS) Subscales Score During DB Phase
Timepoint [17] 0 0
Baseline (DB) to 12 Months of DB Phase
Secondary outcome [18] 0 0
Number of Participants With Treatment-emergent Clinically Significant Abnormal Laboratory Values in Chemistry During DB Phase
Timepoint [18] 0 0
Up to 12 Months of DB Phase
Secondary outcome [19] 0 0
Number of Participants With Treatment-emergent Clinically Significant Abnormal Laboratory Values in Hematology During DB Phase
Timepoint [19] 0 0
Up to 12 Months of DB Phase

Eligibility
Key inclusion criteria
* Must meet the diagnostic criteria for schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5) for at least 6 months before screening
* Must be receiving treatment with paliperidone palmitate (as either the paliperidone palmitate 1-month (PP1M) or paliperidone palmitate 3-month (PP3M) formulation), or injectable risperidone, or any oral antipsychotic
* Must be able, in the opinion of the investigator, to discontinue any antipsychotic medication other than PP1M) or PP3M during the Screening Phase
* Must have a full Positive and Negative Syndrome Scale (PANSS) score of less than (<) 70 points at screening
* Must have a body mass index (BMI) between 17 and 40 kilogram (kg)/meter (m)^2 (inclusive) and must have a body weight of at least 47 kg at screening
* Must be willing to receive gluteal injections of medication during the Double-blind Phase
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

* Must not be receiving any form of involuntary treatment, such as involuntary psychiatric hospitalization, parole-mandated treatment, or court-mandated treatment
* Must not have attempted suicide within 12 months before screening and must not be at imminent risk of suicide or violent behavior, as clinically assessed by the investigator at the time of screening
* Must not have a DSM-5 diagnosis of moderate or severe substance use disorder (except for nicotine and caffeine) within 6 months of screening; however, acute or intermittent substance use prior to screening is not exclusionary, depending upon the clinical judgment of the investigator
* Must not have a history of neuroleptic malignant syndrome or tardive dyskinesia
* Must not have a history of intolerability or severe reactions to moderate or higher doses of antipsychotic medications and must not have any other factors that would, in the judgment of the investigator, indicate that treatment with moderate or higher doses of paliperidone palmitate would be intolerable or unsafe

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
20/11/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
8/05/2020
Sample size
Target
Accrual to date
Final
841
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
The Lyell McEwin Hospital - Elizabeth Vale
Recruitment hospital [2] 0 0
Neuro Trials Victoria - Noble Park
Recruitment postcode(s) [1] 0 0
5112 - Elizabeth Vale
Recruitment postcode(s) [2] 0 0
3174 - Noble Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Kansas
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
North Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
United States of America
State/province [15] 0 0
Utah
Country [16] 0 0
Argentina
State/province [16] 0 0
Ciudad Autónoma De Buenos Aires
Country [17] 0 0
Argentina
State/province [17] 0 0
Cordoba
Country [18] 0 0
Argentina
State/province [18] 0 0
La Plata
Country [19] 0 0
Argentina
State/province [19] 0 0
Rosario
Country [20] 0 0
Brazil
State/province [20] 0 0
Curitiba
Country [21] 0 0
Brazil
State/province [21] 0 0
Itapira
Country [22] 0 0
Brazil
State/province [22] 0 0
Porto Alegre
Country [23] 0 0
Brazil
State/province [23] 0 0
Rio de Janeiro
Country [24] 0 0
Brazil
State/province [24] 0 0
Sao Paulo
Country [25] 0 0
Brazil
State/province [25] 0 0
São Paulo
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Bourgas
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Pazardzhik
Country [28] 0 0
Bulgaria
State/province [28] 0 0
Plovdiv
Country [29] 0 0
Bulgaria
State/province [29] 0 0
Radnevo
Country [30] 0 0
Bulgaria
State/province [30] 0 0
Sofia
Country [31] 0 0
Czechia
State/province [31] 0 0
Brno
Country [32] 0 0
Czechia
State/province [32] 0 0
Hradec Kralove-Vekose
Country [33] 0 0
Czechia
State/province [33] 0 0
Plzen
Country [34] 0 0
Czechia
State/province [34] 0 0
Prague
Country [35] 0 0
Czechia
State/province [35] 0 0
Praha 2
Country [36] 0 0
France
State/province [36] 0 0
Bordeaux
Country [37] 0 0
France
State/province [37] 0 0
Montpellier
Country [38] 0 0
France
State/province [38] 0 0
Nimes Cedex 9
Country [39] 0 0
France
State/province [39] 0 0
Paris
Country [40] 0 0
France
State/province [40] 0 0
Toulon Cedex
Country [41] 0 0
Hong Kong
State/province [41] 0 0
Hong Kong
Country [42] 0 0
Hungary
State/province [42] 0 0
Budapest
Country [43] 0 0
Hungary
State/province [43] 0 0
Gyor
Country [44] 0 0
Hungary
State/province [44] 0 0
Kalocsa
Country [45] 0 0
Hungary
State/province [45] 0 0
Miskolc
Country [46] 0 0
India
State/province [46] 0 0
Ahmedabad
Country [47] 0 0
India
State/province [47] 0 0
Chennai
Country [48] 0 0
India
State/province [48] 0 0
Hyderabad
Country [49] 0 0
India
State/province [49] 0 0
Madurai
Country [50] 0 0
India
State/province [50] 0 0
Mangalore
Country [51] 0 0
India
State/province [51] 0 0
Manipal
Country [52] 0 0
India
State/province [52] 0 0
Pune
Country [53] 0 0
India
State/province [53] 0 0
Varanasi
Country [54] 0 0
Italy
State/province [54] 0 0
Cagliari
Country [55] 0 0
Italy
State/province [55] 0 0
Lecce
Country [56] 0 0
Italy
State/province [56] 0 0
Napoli
Country [57] 0 0
Italy
State/province [57] 0 0
Roma
Country [58] 0 0
Korea, Republic of
State/province [58] 0 0
Gwangju
Country [59] 0 0
Korea, Republic of
State/province [59] 0 0
Gyeonggi-do
Country [60] 0 0
Korea, Republic of
State/province [60] 0 0
Jeonju
Country [61] 0 0
Korea, Republic of
State/province [61] 0 0
Seoul
Country [62] 0 0
Malaysia
State/province [62] 0 0
Ipoh
Country [63] 0 0
Malaysia
State/province [63] 0 0
Kuala Lumpur
Country [64] 0 0
Malaysia
State/province [64] 0 0
Kuching
Country [65] 0 0
Mexico
State/province [65] 0 0
Mexico City
Country [66] 0 0
Mexico
State/province [66] 0 0
Monterrey
Country [67] 0 0
Mexico
State/province [67] 0 0
San Luis Potosí
Country [68] 0 0
Poland
State/province [68] 0 0
Bialystok
Country [69] 0 0
Poland
State/province [69] 0 0
Chelmno
Country [70] 0 0
Poland
State/province [70] 0 0
Gdansk
Country [71] 0 0
Poland
State/province [71] 0 0
Gorlice
Country [72] 0 0
Poland
State/province [72] 0 0
Leszno
Country [73] 0 0
Poland
State/province [73] 0 0
Lublin
Country [74] 0 0
Poland
State/province [74] 0 0
Pruszcz Gdanski
Country [75] 0 0
Poland
State/province [75] 0 0
Pruszkow
Country [76] 0 0
Poland
State/province [76] 0 0
Torun
Country [77] 0 0
Russian Federation
State/province [77] 0 0
Ekaterinburg
Country [78] 0 0
Russian Federation
State/province [78] 0 0
Moscow
Country [79] 0 0
Russian Federation
State/province [79] 0 0
Nizny Novgorod
Country [80] 0 0
Russian Federation
State/province [80] 0 0
Saratov
Country [81] 0 0
Russian Federation
State/province [81] 0 0
St-Petersburg
Country [82] 0 0
Russian Federation
State/province [82] 0 0
St.Peterburg
Country [83] 0 0
Russian Federation
State/province [83] 0 0
Tomsk
Country [84] 0 0
South Africa
State/province [84] 0 0
Cape Town
Country [85] 0 0
South Africa
State/province [85] 0 0
Pretoria
Country [86] 0 0
South Africa
State/province [86] 0 0
Welgemoed
Country [87] 0 0
Spain
State/province [87] 0 0
Barcelona
Country [88] 0 0
Spain
State/province [88] 0 0
Bilbao
Country [89] 0 0
Spain
State/province [89] 0 0
Oviedo
Country [90] 0 0
Spain
State/province [90] 0 0
Ponferrada
Country [91] 0 0
Spain
State/province [91] 0 0
Valencia
Country [92] 0 0
Spain
State/province [92] 0 0
Zamora
Country [93] 0 0
Taiwan
State/province [93] 0 0
Tainan
Country [94] 0 0
Taiwan
State/province [94] 0 0
Taipei
Country [95] 0 0
Taiwan
State/province [95] 0 0
Taoyuan
Country [96] 0 0
Turkey
State/province [96] 0 0
Ankara
Country [97] 0 0
Turkey
State/province [97] 0 0
Istanbul
Country [98] 0 0
Turkey
State/province [98] 0 0
Konya
Country [99] 0 0
Turkey
State/province [99] 0 0
Sakarya
Country [100] 0 0
Ukraine
State/province [100] 0 0
Glevakha
Country [101] 0 0
Ukraine
State/province [101] 0 0
Kharkiv
Country [102] 0 0
Ukraine
State/province [102] 0 0
Kherson
Country [103] 0 0
Ukraine
State/province [103] 0 0
Kyiv
Country [104] 0 0
Ukraine
State/province [104] 0 0
Lviv
Country [105] 0 0
Ukraine
State/province [105] 0 0
Oleksandrivka
Country [106] 0 0
Ukraine
State/province [106] 0 0
Smila
Country [107] 0 0
Ukraine
State/province [107] 0 0
Vinnytsia

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT03345342